Author name: Ananta Kar

India’s pharmaceutical industry is simultaneously pursuing two revolutionary paths that seem unrelated but share a common thread—saving lives more ethically and effectively. The country recently eliminated mandatory animal testing for drug development whilst simultaneously ramping up efforts against antimicrobial resistance that threatens to kill 10 million people annually by 2050. These aren’t minor policy adjustments

India’s biotechnology sector buzzes with potential, yet a frustrating disconnect persists between government promises and ground realities. Whilst the Department of Biotechnology launches ambitious schemes worth thousands of crores, startup founders in Bengaluru and Hyderabad tell different stories. They speak of delayed funding, bureaucratic labyrinths, and support that sounds impressive on paper but rarely materialises

There’s a particular irony in modern medicine: the most sophisticated treatments often look deceptively simple. A clear vial containing colourless liquid might cost thousands of pounds per dose, yet inside swim precisely engineered proteins capable of seeking out and destroying cancer cells whilst leaving healthy tissue untouched. These are monoclonal antibodies—amongst the most revolutionary therapeutics